September 30, 2020

The Niche

Knoepfler lab stem cell blog

Fate Therapeutics

3 min read

We’ve had another week of interesting stem cell news and papers. Here is an aggregate of the stem cell and regenerative medicine week that was. Stem cell therapy for baldness I’ve covered stem cells for hair loss for about a decade here on The Niche. While it seems like it’s taken a long time for this work to advance, there has been concrete progress. From Nature News, Regenerative medicine could pave the way to treating baldness. Here’s the actual Nature paper in question: Hair-bearing human …Read More

3 min read

There’s nothing like stem cell good news and interesting publications to perk one up on a Monday. Enjoy. What recent papers have struck you as exciting? Novel stem cell-based cancer approaches (Part 1) It was exciting when Fate Therapeutics got the first induced pluripotent stem cell (IPSC) IND in the U.S. for their IPSC-derived natural killer cell (NK) product. Now in another milestone the first patient has received the investigational NK therapy at UC San Diego. From UCSD, “After 10 years in remission, Derek Ruff’s cancer …Read More

2 min read

In the past month or two there has been a steady stream of good news in the stem cell and regenerative medicine world. Here are three examples. Fate Therapeutics announced the first US IND for an induced pluripotent stem cell (IPSC)-related product. Its cleared product, FT500, is an off-the-shelf natural killer-based cancer immunotherapy. I expect more to come in the next couple years so good news now and likely more to come. IPSC-based trials are picking up in Japan too with trials related to …Read More

5 min read

Each year I make a list of stem cell predictions for the following year and I’ll release my predictions for 2019 soon, but first I’m grading how my 20 predictions for 2018 turned out. It seems I did better than usual predicting what would happen this year. I only got a couple partial credit or were hard to grade. The rest were right. Here are my 20 predictions verbatim that I made in late 2017 for what would happen in 2018. 1. Combo cell-gene …Read More